Details

Autor(en) / Beteiligte

• Kawamura, Tatsuya
• Yamamura, Takeshi
• Nakamura, Masanao
• Maeda, Keiko
• Sawada, Tsunaki
• Ishikawa, Eri
• Iida, Tadashi
• Mizutani, Yasuyuki
• Ishikawa, Takuya
• Kakushima, Naomi
• Furukawa, Kazuhiro
• Ohno, Eizaburo
• Honda, Takashi
• Kawashima, Hiroki
• Ishigami, Masatoshi

Titel

Accuracy of Serum Leucine-Rich Alpha-2 Glycoprotein in Evaluating Endoscopic Disease Activity in Crohn’s Disease

Ist Teil von

• Inflammatory bowel diseases, 2023-02, Vol.29 (2), p.245-253

Ort / Verlag

US: Oxford University Press

Erscheinungsjahr

2023

Link zum Volltext

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• Abstract Background Mucosal healing, confirmed by endoscopic evaluation, is the long-term goal of treatment for Crohn’s disease (CD). Leucine-rich alpha-2 glycoprotein (LRG) is a new serum biomarker correlated with disease activity in inflammatory bowel disease. However, studies evaluating its relationship with CD, particularly in the context of small intestinal lesions, are scarce. The aim of this study was to investigate the accuracy of LRG in assessing endoscopic activity, especially remission, in patients with CD. Methods Between July 2020 and March 2021, 72 patients with CD who underwent LRG testing and double-balloon endoscopy at the same time were included. Endoscopic activity was evaluated using the applied Simple Endoscopic Score for Crohn’s disease, including small intestine lesions. The relationship of LRG with clinical symptoms and endoscopic activity was assessed, and its predictive accuracy was evaluated. Results Leucine-rich alpha-2 glycoprotein showed a significant positive correlation with endoscopic activity (r = 0.619, P < .001), even in patients with active lesions in the small intestine (r = 0.626, P < .001). Multivariate logistic regression revealed that LRG was the only factor associated with endoscopic remission. An LRG cutoff value of 8.9 μg/mL had a sensitivity of 93.3%; specificity of 83.3%; positive predictive value of 96.6%; negative predictive value of 71.4%; accuracy of 91.7%; and area under the curve of 0.904 for the prediction of endoscopic remission. Conclusions Leucine-rich alpha-2 glycoprotein can be used in assessing endoscopic activity and is a reliable marker of endoscopic remission in CD patients. It can be an intermediate target in the treatment of CD. Lay Summary This study investigated leucine-rich alpha-2 glycoprotein’s ability to assess endoscopic activity and endoscopic remission in patients with CD. The results showed that leucine-rich alpha-2 glycoprotein can assess endoscopic activity in CD patients and is a reliable marker of endoscopic remission. Graphical Abstract Graphical Abstract